News
A San Francisco-based biopharma company developing a topical protein therapy for dystrophic epidermolysis bullosa (DEB).
US pharma giant Merck & Co has started building a $1 billion, 470,000-square-foot biologics center of excellence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback